Status:
ACTIVE_NOT_RECRUITING
Electromechanically Optimised Right Ventricular Pacing In Hypertrophic Cardiomyopathy (EMORI-HCM)
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
British Heart Foundation
Conditions:
Hypertrophic Cardiomyopathy
Hypertrophic Obstructive Cardiomyopathy
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
Hypertrophic Obstructive Cardiomyopathy (HOCM) is an inherited cardiac condition which causes the heart muscle to become abnormally thick causing obstruction of blood flow in the heart. This causes de...
Detailed Description
1. To test the impact of changing the pacing site and how it affects intra-ventricular delay and the amount of dyssynchrony. At the time of device implant, the RV lead will be positioned temporari...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- All patients will have a clinical diagnosis of HOCM with an LVOT gradient of at least 30 mmHg, at rest or provoked.
- Symptomatic patients
- Can have co-existing mid-cavity obstruction.
- HOCM patients referred for Dual Chamber Pacemaker / ICD Implantation.
- Adults willing to take part (ages 18 - 100 years old)
- Able to give consent.
- Exclusion criteria:
- Unable to give consent
- Children age \< 18 years or adults \> 100 years old
- Pregnant patient
- Patients with persistent Atrial Fibrillation or high grade Atrio-Ventricular Block
Exclusion
Key Trial Info
Start Date :
March 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 16 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05257772
Start Date
March 14 2022
End Date
May 16 2025
Last Update
May 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Heart & Lung Institute, Imperial College London
London, United Kingdom, W12 0HS